Alnylam Pharmaceuticals (NASDAQ:ALNY) EVP Tolga Tanguler Sells 1,396 Shares

Key Points

• Alnylam Pharmaceuticals' EVP, Tolga Tanguler, sold 1,396 shares at an average price of $453.27, totaling approximately $632,765, resulting in a 4.52% decrease in their overall position.
• The company reported $0.32 earnings per share for the last quarter, significantly surpassing analysts' expectations of ($0.54), with revenues increasing by 17.3% compared to the previous year.
• Analyst upgrades for Alnylam have raised price targets significantly, with Piper Sandler and Barclays setting targets at $449 and $460, respectively, indicating a positive outlook for the stock.

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Get Free Report) EVP Tolga Tanguler sold 1,396 shares of the firm's stock in a transaction that occurred on Monday, August 18th. The stock was sold at an average price of $453.27, for a total transaction of $632,764.92. Following the completion of the sale, the executive vice president owned 29,466 shares in the company, valued at $13,356,053.82. This represents a 4.52% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

Alnylam Pharmaceuticals Stock Performance

ALNY stock traded up $1.41 on Tuesday, hitting $458.28. The company had a trading volume of 1,321,747 shares, compared to its average volume of 957,852. Alnylam Pharmaceuticals, Inc. has a 12-month low of $205.87 and a 12-month high of $462.88. The company has a current ratio of 2.80, a quick ratio of 2.75 and a debt-to-equity ratio of 4.10. The stock's 50-day simple moving average is $348.15 and its 200 day simple moving average is $291.81. The stock has a market cap of $60.07 billion, a price-to-earnings ratio of -185.54 and a beta of 0.25.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last issued its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported $0.32 earnings per share for the quarter, topping the consensus estimate of ($0.54) by $0.86. The business had revenue of $773,689 billion for the quarter, compared to analysts' expectations of $633.54 million. Alnylam Pharmaceuticals had a negative net margin of 12.96% and a negative return on equity of 273.52%. The company's revenue was up 17.3% compared to the same quarter last year. During the same quarter last year, the company posted ($0.13) EPS. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, equities research analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Institutional Trading of Alnylam Pharmaceuticals

A number of large investors have recently made changes to their positions in the business. Vanguard Group Inc. increased its holdings in shares of Alnylam Pharmaceuticals by 1.8% in the 2nd quarter. Vanguard Group Inc. now owns 13,297,139 shares of the biopharmaceutical company's stock worth $4,336,064,000 after buying an additional 240,534 shares during the last quarter. T. Rowe Price Investment Management Inc. boosted its stake in shares of Alnylam Pharmaceuticals by 0.8% during the 1st quarter. T. Rowe Price Investment Management Inc. now owns 4,418,145 shares of the biopharmaceutical company's stock worth $1,192,988,000 after purchasing an additional 33,696 shares during the period. Price T Rowe Associates Inc. MD boosted its stake in shares of Alnylam Pharmaceuticals by 5.6% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,505,168 shares of the biopharmaceutical company's stock worth $946,466,000 after purchasing an additional 185,783 shares during the period. Geode Capital Management LLC boosted its stake in shares of Alnylam Pharmaceuticals by 3.3% during the 2nd quarter. Geode Capital Management LLC now owns 2,398,770 shares of the biopharmaceutical company's stock worth $779,857,000 after purchasing an additional 75,936 shares during the period. Finally, Orbis Allan Gray Ltd boosted its stake in shares of Alnylam Pharmaceuticals by 29.8% during the 2nd quarter. Orbis Allan Gray Ltd now owns 2,121,412 shares of the biopharmaceutical company's stock worth $691,771,000 after purchasing an additional 486,489 shares during the period. 92.97% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

ALNY has been the topic of several analyst reports. Piper Sandler lifted their price target on shares of Alnylam Pharmaceuticals from $304.00 to $449.00 and gave the stock an "overweight" rating in a research note on Friday, August 1st. Barclays lifted their target price on shares of Alnylam Pharmaceuticals from $329.00 to $460.00 and gave the company an "overweight" rating in a research note on Friday, August 1st. JPMorgan Chase & Co. lifted their target price on shares of Alnylam Pharmaceuticals from $348.00 to $475.00 and gave the company an "overweight" rating in a research note on Wednesday, August 6th. Bank of America lifted their target price on shares of Alnylam Pharmaceuticals from $336.00 to $359.00 and gave the company a "buy" rating in a research note on Friday, July 11th. Finally, Needham & Company LLC lifted their price target on shares of Alnylam Pharmaceuticals from $377.00 to $478.00 and gave the company a "buy" rating in a report on Thursday, July 31st. Twenty-two analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat, Alnylam Pharmaceuticals presently has an average rating of "Moderate Buy" and an average price target of $405.33.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.